NCT04082936

A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

Public trial-level signal summary for this oncology Phase 2 record.

Record overview

Status and phase

Status: TERMINATED

Phase: PHASE1, PHASE2

Sponsor: IGM Biosciences, Inc.

Condition: Non-Hodgkin Lymphoma, Follicular Lymphoma, DLBCL, Mantle Cell Lymphoma, Marginal Zone Lymphoma

Signal summary

Status signal: Registry Stop Signal

Timeline signals: stale_update_signal

Results signal: Low Signal

Operational burden: None

Stopped reason

Strategic Pipeline Prioritization: Clinical development of imvotamab in autoimmune diseases prioritized.